Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration.

Kashani AH, Lebkowski JS, Rahhal FM, Avery RL, Salehi-Had H, Dang W, Lin CM, Mitra D, Zhu D, Thomas BB, Hikita ST, Pennington BO, Johnson LV, Clegg DO, Hinton DR, Humayun MS.

Sci Transl Med. 2018 Apr 4;10(435). pii: eaao4097. doi: 10.1126/scitranslmed.aao4097.

PMID:
29618560
2.

Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cells: Preclinical Efficacy and Safety in Cervical Spinal Cord Injury.

Manley NC, Priest CA, Denham J, Wirth ED 3rd, Lebkowski JS.

Stem Cells Transl Med. 2017 Oct;6(10):1917-1929. doi: 10.1002/sctm.17-0065. Epub 2017 Aug 22.

3.

Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia.

Khoury HJ, Collins RH Jr, Blum W, Stiff PS, Elias L, Lebkowski JS, Reddy A, Nishimoto KP, Sen D, Wirth ED 3rd, Case CC, DiPersio JF.

Cancer. 2017 Aug 15;123(16):3061-3072. doi: 10.1002/cncr.30696. Epub 2017 Apr 14.

PMID:
28411378
4.

Preclinical safety of human embryonic stem cell-derived oligodendrocyte progenitors supporting clinical trials in spinal cord injury.

Priest CA, Manley NC, Denham J, Wirth ED 3rd, Lebkowski JS.

Regen Med. 2015 Nov;10(8):939-58. doi: 10.2217/rme.15.57. Epub 2015 Sep 8.

5.

Response to Frederic Bretzner et al. "Target populations for first-in-human embryonic stem cell research in spinal cord injury".

Wirth E 3rd, Lebkowski JS, Lebacqz K.

Cell Stem Cell. 2011 May 6;8(5):476-8. doi: 10.1016/j.stem.2011.04.008.

6.

Modification of human embryonic stem cell-derived dendritic cells with mRNA for efficient antigen presentation and enhanced potency.

Nishimoto KP, Tseng SY, Lebkowski JS, Reddy A.

Regen Med. 2011 May;6(3):303-18. doi: 10.2217/rme.11.19.

PMID:
21548736
7.

Interview: Discussions on the development of human embryonic stem cell-based therapies.

Lebkowski JS.

Regen Med. 2009 Sep;4(5):659-61. doi: 10.2217/rme.09.49.

8.

Generation of immunogenic dendritic cells from human embryonic stem cells without serum and feeder cells.

Tseng SY, Nishimoto KP, Silk KM, Majumdar AS, Dawes GN, Waldmann H, Fairchild PJ, Lebkowski JS, Reddy A.

Regen Med. 2009 Jul;4(4):513-26. doi: 10.2217/rme.09.25.

9.

In vivo characterization of transplanted human embryonic stem cell-derived pancreatic endocrine islet cells.

Eshpeter A, Jiang J, Au M, Rajotte RV, Lu K, Lebkowski JS, Majumdar AS, Korbutt GS.

Cell Prolif. 2008 Dec;41(6):843-858. doi: 10.1111/j.1365-2184.2008.00564.x.

PMID:
19040565
10.

Basic fibroblast growth factor supports undifferentiated human embryonic stem cell growth without conditioned medium.

Xu C, Rosler E, Jiang J, Lebkowski JS, Gold JD, O'Sullivan C, Delavan-Boorsma K, Mok M, Bronstein A, Carpenter MK.

Stem Cells. 2005 Mar;23(3):315-23.

12.

Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.

Irving J, Wang Z, Powell S, O'Sullivan C, Mok M, Murphy B, Cardoza L, Lebkowski JS, Majumdar AS.

Cancer Gene Ther. 2004 Mar;11(3):174-85.

PMID:
14726958
13.

Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors.

Frolkis M, Fischer MB, Wang Z, Lebkowski JS, Chiu CP, Majumdar AS.

Cancer Gene Ther. 2003 Mar;10(3):239-49.

PMID:
12637945
14.

Human embryonic stem cells: culture, differentiation, and genetic modification for regenerative medicine applications.

Lebkowski JS, Gold J, Xu C, Funk W, Chiu CP, Carpenter MK.

Cancer J. 2001 Nov-Dec;7 Suppl 2:S83-93.

PMID:
11777269
15.
16.

Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J, Gilboa E.

Nat Med. 2000 Sep;6(9):1011-7.

PMID:
10973321
17.

Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site.

Wright SE, Kilinski L, Talib S, Lowe KE, Burnside JS, Wu JY, Dolby N, Dombrowski KE, Lebkowski JS, Philip R.

J Immunother. 2000 Jan;23(1):2-10.

PMID:
10687132
18.

Telomerase. A target for anticancer therapy.

Lichtsteiner SP, Lebkowski JS, Vasserot AP.

Ann N Y Acad Sci. 1999;886:1-11. Review.

PMID:
10667198
19.

Animal serum-free culture of purified human CD34+ cells: amplification of progenitors from G-CSF and GM-CSF-mobilized peripheral blood.

Schain LR, Jain S, Wysocki M, Hall M, Dadey B, Pennathur-Das R, Biddle W, Wolf J, Okarma TB, Lebkowski JS.

J Hematother. 1997 Aug;6(4):335-49.

PMID:
9377072
20.

Breast cancer: cell and gene therapy.

Lebkowski JS, Philip R, Okarma TB.

Cancer Invest. 1997;15(6):568-76. Review. No abstract available.

PMID:
9412663
21.

Selection of murine lymphoid and hematopoietic cells using polystyrene tissue culture devices containing covalently immobilized antibody.

Berson AE, Knobel KM, Rood D, Chen K, Lamons D, McNally MA, Okarma TB, Lebkowski JS.

Biotechniques. 1996 Jun;20(6):1098-103.

PMID:
8780881
22.

The challenges of recombinant adeno-associated virus manufacturing: alternative use of adeno-associated virus plasmid/liposome complexes for gene therapy applications.

Lebkowski JS, Okarma TB, Philip R.

Curr Top Microbiol Immunol. 1996;218:51-9. Review. No abstract available.

PMID:
8794245
23.

Serum-free culture of hematopoietic stem cells: a review.

Lebkowski JS, Schain LR, Okarma TB.

Stem Cells. 1995 Nov;13(6):607-12. Review.

PMID:
8590862
24.

Isolation of small, primitive human hematopoietic stem cells: distribution of cell surface cytokine receptors and growth in SCID-Hu mice.

Wagner JE, Collins D, Fuller S, Schain LR, Berson AE, Almici C, Hall MA, Chen KE, Okarma TB, Lebkowski JS.

Blood. 1995 Jul 15;86(2):512-23.

25.

Retention of endocrine function in the SCID-Hu pancreas mouse--a model for the development of human fetal islet tissue.

Goldrath AW, Chen KE, Weide LG, Pour PM, Lebkowski JS, Alters SE.

Transplantation. 1995 May 27;59(10):1497-500. No abstract available.

PMID:
7770944
26.

Long-term reconstitution of mice after ex vivo expansion of bone marrow cells: differential activity of cultured bone marrow and enriched stem cell populations.

Knobel KM, McNally MA, Berson AE, Rood D, Chen K, Kilinski L, Tran K, Okarma TB, Lebkowski JS.

Exp Hematol. 1994 Dec;22(13):1227-35.

PMID:
7957709
27.

Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes.

Philip R, Brunette E, Kilinski L, Murugesh D, McNally MA, Ucar K, Rosenblatt J, Okarma TB, Lebkowski JS.

Mol Cell Biol. 1994 Apr;14(4):2411-8.

28.

Separation of lectin-binding cells using polystyrene culture devices with covalently immobilized soybean agglutinin.

Schain LR, Okrongly D, Okarma TB, Lebkowski JS.

J Hematother. 1994 Spring;3(1):37-46.

PMID:
7922007
29.

Rapid isolation and serum-free expansion of human CD34+ cells.

Lebkowski JS, Schain L, Hall M, Wysocki M, Dadey B, Biddle W.

Blood Cells. 1994;20(2-3):404-10.

PMID:
7538346
30.
31.

Human umbilical cord blood CD34+ cell purification with high yield of early progenitors.

Cardoso AA, Li ML, Batard P, Sansilvestri P, Hatzfeld A, Levesque JP, Lebkowski JS, Hatzfeld J.

J Hematother. 1993 Summer;2(2):275-9.

PMID:
7522882
32.

Rapid isolation of human CD34 hematopoietic stem cells--purging of human tumor cells.

Lebkowski JS, Schain LR, Okrongly D, Levinsky R, Harvey MJ, Okarma TB.

Transplantation. 1992 May;53(5):1011-9.

PMID:
1374943
33.

Enrichment of murine hematopoietic stem cells. Reconstitution of syngeneic and haplotype-mismatched mice.

Lebkowski JS, McNally MA, Finch S, Manzagol S, Pletcher A, Schain LR, Okarma TB.

Transplantation. 1990 Dec;50(6):1019-27.

PMID:
1979451
34.

Comparison of ultraviolet irradiation-induced mutagenesis of the lacI gene in Escherichia coli and in human 293 cells.

Hsia HC, Lebkowski JS, Leong PM, Calos MP, Miller JH.

J Mol Biol. 1989 Jan 5;205(1):103-13.

PMID:
2647996
35.

Optimizing electroporation parameters for a variety of human hematopoietic cell lines.

McNally MA, Lebkowski JS, Okarma TB, Lerch LB.

Biotechniques. 1988 Oct;6(9):882-6.

PMID:
3273199
36.
37.

Inducible gene expression from multiple promoters by the tumor-promoting agent, PMA.

Lebkowski JS, McNally MA, Okarma TB, Lerch LB.

Nucleic Acids Res. 1987 Nov 11;15(21):9043-55.

38.
39.

The lacI shuttle: rapid analysis of the mutagenic specificity of ultraviolet light in human cells.

Lebkowski JS, Clancy S, Miller JH, Calos MP.

Proc Natl Acad Sci U S A. 1985 Dec;82(24):8606-10.

40.

Simian virus 40 replication in adenovirus-transformed human cells antagonizes gene expression.

Lebkowski JS, Clancy S, Calos MP.

Nature. 1985 Sep 12-18;317(6033):169-71.

PMID:
2993921
41.

Specificity of mutations induced in transfected DNA by mammalian cells.

Miller JH, Lebkowski JS, Greisen KS, Calos MP.

EMBO J. 1984 Dec 20;3(13):3117-21.

42.

Transfected DNA is mutated in monkey, mouse, and human cells.

Lebkowski JS, DuBridge RB, Antell EA, Greisen KS, Calos MP.

Mol Cell Biol. 1984 Oct;4(10):1951-60.

43.

Interphase nuclear matrix and metaphase scaffolding structures.

Lewis CD, Lebkowski JS, Daly AK, Laemmli UK.

J Cell Sci Suppl. 1984;1:103-22.

PMID:
6397468
44.

High mutation frequency in DNA transfected into mammalian cells.

Calos MP, Lebkowski JS, Botchan MR.

Proc Natl Acad Sci U S A. 1983 May;80(10):3015-9.

45.

Evidence for two levels of DNA folding in histone-depleted HeLa interphase nuclei.

Lebkowski JS, Laemmli UK.

J Mol Biol. 1982 Apr 5;156(2):309-24. No abstract available.

PMID:
7086903
46.

Non-histone proteins and long-range organization of HeLa interphase DNA.

Lebkowski JS, Laemmli UK.

J Mol Biol. 1982 Apr 5;156(2):325-44. No abstract available.

PMID:
6896344

Supplemental Content

Loading ...
Support Center